Session Abstract – PMWC 2020 Silicon Valley


Frequently, markers identified from NGS profiled tumors are translated into ddPCR assays which enable precision monitoring of a patient over the course of disease and even after health has been restored. This session will illustrate with a number of clinical use cases how dPCR (as demonstrated by ddPCR) is a fit-for-purpose technology approach for serial monitoring of multiple markers in cancer patients. This includes a diversity of marker types such as SNV’s and indels (both driver and passenger), and gene fusions from both truncal rearrangements and drivers of tumorigenesis.

 Speaker Profile

Ph.D., Director of Scientific Affairs, Digital Biology Center, Bio-Rad Laboratories

Biography
Dr. George Karlin-Neumann is the Director of Scientific Affairs at Bio-Rad’s Digital Biology Center, formerly Quantalife. There he is helping to drive the research and clinical adoption of digital genomic technologies through collaborations and internal research programs. He joined QuantaLife in 2010 as Sr. Director of Molecular Diagnostics where he contributed to the development of what has become Bio-Rad’s highly successful QX200 Droplet Digital PCR System. A molecular geneticist and biotechnologist by training, in 2001 he co-founded the high throughput genomics company, ParAllele BioScience, out of the Stanford Genome Technology Center. It was acquired by Affymetrix in 2005 where he continued developing state-of-the-art assays for cancer copy number variation and for pharmacogenomic profiling. He received his PhD from UCLA in 1990 for innovative studies using conditional lethal mutant screens in Arabidopsis and then continued related work during a postdoctoral fellowship with Dr. Ronald Davis in the Stanford Biochemistry Department. Prior to leaving Stanford to found ParAllele, he spent five years as the co-PI on an NSF-funded Plant Sensory Network Consortium grant where he developed and disseminated DNA microarray technology to partnering institutions.


 Speaker Profile

Ph.D., Staff Scientist, Breast Cancer Now Research Centre, The Institute of Cancer Research

Biography
Dr Isaac Garcia-Murillas is a Staff Scientist at the Breast Cancer Now Research Centre at The Institute of Cancer Research in London. Dr Garcia-Murillas leads and develops the use of Next Generation Sequencing (NGS) and digital PCR (dPCR) technologies to study circulating tumor DNA (ctDNA) from liquid biopsies. His research interests converge in the clinical utility of ctDNA as a potential biomarker to quantify Minimal Residual Disease, monitor response to treatment, stratify patients to targeted therapies and identify the emergence of drug resistance. Dr Garcia-Murillas read Genetics and Immunology at the University of Aberdeen as an undergraduate student before undertaking his Ph.D. at The University of Cambridge where he worked in the role of lipids as intracellular second messengers. Dr Garcia-Murillas continued his research on signaling pathways as a Postdoctoral Fellow at The Institute of Cancer Research before undertaking his current position.


 Speaker Profile

M.D., Associate Professor & Senior Associate Director, Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford Genome Technology Center

Biography
Dr. Hanlee Ji graduated in 1994 from John Hopkins School of Medicine in Internal Medicine and went on to specialize in Oncology. He is currently the Assistant Professor, Medicine – Oncology at Stanford University CA. His research group is pursuing projects focused on personalized medicine. Specifically, he is interested in using genetic and genomic approaches in oncology to improve targeted cancer therapy, make accurate prognosis, predict cancer therapy efficacy and identify clinically relevant cancer mutations.


 Speaker Profile

Ph.D., Head, Translational Genomics and Epigenomics, Olivia Newton-John Cancer Research Institute

Biography
Alexander Dobrovic Ph.D. leads the Translational Genomics Laboratory at the Austin Hospital in Melbourne, Australia. His lab has a focus on personalized medicine including both research, and developing and implementing innovative, clinically relevant affordable methodologies. His lab is accredited for medical testing for tissue and liquid biopsy assays for mutations both for diagnostics and cancer monitoring. DNA methylation assays (BRCA1, MLH1, and MGMT) and solid cancer fusions using next-generation sequencing. He is a committee member of the annual Thomas Ashworth Liquid Biopsy Symposium and the Australian Genomic Cancer Clinical Trials Initiative.